0001179110-16-031541.txt : 20161114 0001179110-16-031541.hdr.sgml : 20161111 20161114174946 ACCESSION NUMBER: 0001179110-16-031541 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161109 FILED AS OF DATE: 20161114 DATE AS OF CHANGE: 20161114 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Knopf John L CENTRAL INDEX KEY: 0001586745 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 161996721 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2016-11-09 0 0001280600 ACCELERON PHARMA INC XLRN 0001586745 Knopf John L 128 SIDNEY STREET CAMBRIDGE MA 02139 1 1 0 0 CEO and President Common Stock 2016-11-09 4 M 0 31543 5.88 A 245627 D Common Stock 2016-11-09 4 M 0 37500 5.28 A 283127 D Common Stock 2016-11-09 4 M 0 9375 5.28 A 292502 D Common Stock 2016-11-09 4 M 0 15976 5.28 A 308478 D Common Stock 2016-11-09 4 M 0 5606 5.08 A 314084 D Common Stock 2016-11-09 4 S 0 100000 32.19 D 214084 D Option to Purchase Common Stock 5.88 2016-11-09 4 M 0 31543 0 D 2020-02-04 Common Stock 31543 18457 D Option to Purchase Common Stock 5.28 2016-11-09 4 M 0 37500 0 D 2021-12-16 Common Stock 37500 12500 D Option to Purchase Common Stock 5.28 2016-11-09 4 M 0 9375 0 D 2022-11-13 Common Stock 9375 28125 D Option to Purchase Common Stock 5.28 2016-11-09 4 M 0 15976 0 D 2022-11-13 Common Stock 15976 21524 D Option to Purchase Common Stock 5.08 2016-11-09 4 M 0 5606 0 D 2018-03-27 Common Stock 5606 109027 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.98, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant. The options of registrant's common stock vested over three years, with the first vesting three months after the achievement of the appropriate performance trigger. If the performance trigger was not achieved, the options vested on the four year anniversary of the grant. /s/ John D. Quisel, as attorney-in-fact for John L. Knopf 2016-11-14